Fig. 2.

Percentage of male and female patients treated with ixekizumab Q2W achieving ACR20/50/70 (a, b), MDA/VLDA (c, d), and DAPSA LDA/DAPSA Remission (e, f) through 156 weeks. Missing data were imputed by mNRI. P values were calculated for proportions of male vs. female responders; *P < 0.05, ^‡P < 0.01, ^†P < 0.001. DAPSA Disease Activity Index for Psoriatic Arthritis, LDA low disease activity, MDA minimal disease activity, Ns number of patients in the subgroup, VLDA very low disease activity, Q2W every 2 weeks